Strong domestic demand and exports to semi-regulated markets are expected to drive revenue growth for the pharmaceuticals sector in the current fiscal year (FY23), though export demand from regulated markets is expected to remain moderate owing to high pricing pressure amid intense competition.
In December, the domestic pharmaceuticals market grew 10.4 per cent on exceptional growth in both volume sales and prices. However, this growth was led by anti-infective therapeutics and could taper in coming months.
In this milieu, small and medium enterprises (SMEs), which have a 30-40 per cent share in industry revenue, are expected to grow 7-9 per cent in FY23, compared with 6-8 per cent in FY22. Growth would be led by domestic demand, while exports, which account for about 45 per cent of industry revenue, remain weak.
TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST RS 249 A MONTH.
Subscribe To Insights
Key stories on business-standard.com are available to premium subscribers only.Already a BS Premium subscriber? Log in NOW
Or